Is spontaneous echo contrast associated with device-related thrombus or embolic events after left atrial appendage occlusion? - Insights from the multicenter German LAARGE registry.
Atrial fibrillation
Bleeding risk
Interventional approach
Ischemic stroke
Left atrial appendage closure
Thromboembolism
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
28
02
2023
accepted:
12
05
2023
medline:
1
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
aheadofprint
Résumé
Interventional left atrial appendage occlusion (LAAO) provides an alternative to oral anticoagulation (OAC) for prophylaxis of thromboembolic events (TEs) in nonvalvular atrial fibrillation patients, predominantly in those with high bleeding risk and contraindications for long-term OAC. Although spontaneous echo contrast (SEC) is a well-known risk factor for atrial thrombus formation, little is known about whether this means an increased risk of device-related thrombus (DRT) or TEs following LAAO. This substudy of the prospective, multicenter German LAARGE registry assessed two groups according to absence (SEC -) or presence of SEC (SEC +) in preprocedural cardiac imaging. Clinical and echocardiographic parameters were registered up to 1 year after LAAO. Five hundred eighty-eight patients (SEC - 85.5 vs. SEC + 14.5%) were included. More SEC + patients were implanted for OAC non-compliance (11.8 vs. 4.6%, p = 0.008) and a higher proportion received only antiplatelet therapy without OAC at hospital discharge (96.5 vs. 86.0%, p = 0.007). The SEC + patients had larger LA diameters (50 (47; 54) vs. 47 (43; 51) mm, p < 0.001), wider LAA ostia (21 (19; 23) vs. 20 (17; 22) mm at 45°, p = 0.011), and lower left ventricular ejection fraction (50 (45; 60) vs. 60 (50; 60) %, p < 0.001) on admission. Procedural success was very high in both groups (98.1%, p = 1.00). Periprocedural major adverse cardiac and cerebrovascular events and other major complications were rare in both groups (3.8 vs. 4.7%, p = 0.76). At follow-up, DRT was only detected in the SEC - group (3.8 vs. 0%, p = 1.00). The rates of TEs (SEC - 1.2 vs. SEC + 0%, p = 1.00) after hospital discharge and 1-year mortality (SEC - 12.0 vs. SEC + 11.8%, p = 0.96) were not significantly different between the two groups. Presence of SEC at baseline was not associated with an increased rate of DRT or TEs at 1-year follow-up after LAAO in LAARGE.
Sections du résumé
BACKGROUND
BACKGROUND
Interventional left atrial appendage occlusion (LAAO) provides an alternative to oral anticoagulation (OAC) for prophylaxis of thromboembolic events (TEs) in nonvalvular atrial fibrillation patients, predominantly in those with high bleeding risk and contraindications for long-term OAC. Although spontaneous echo contrast (SEC) is a well-known risk factor for atrial thrombus formation, little is known about whether this means an increased risk of device-related thrombus (DRT) or TEs following LAAO.
METHODS
METHODS
This substudy of the prospective, multicenter German LAARGE registry assessed two groups according to absence (SEC -) or presence of SEC (SEC +) in preprocedural cardiac imaging. Clinical and echocardiographic parameters were registered up to 1 year after LAAO.
RESULTS
RESULTS
Five hundred eighty-eight patients (SEC - 85.5 vs. SEC + 14.5%) were included. More SEC + patients were implanted for OAC non-compliance (11.8 vs. 4.6%, p = 0.008) and a higher proportion received only antiplatelet therapy without OAC at hospital discharge (96.5 vs. 86.0%, p = 0.007). The SEC + patients had larger LA diameters (50 (47; 54) vs. 47 (43; 51) mm, p < 0.001), wider LAA ostia (21 (19; 23) vs. 20 (17; 22) mm at 45°, p = 0.011), and lower left ventricular ejection fraction (50 (45; 60) vs. 60 (50; 60) %, p < 0.001) on admission. Procedural success was very high in both groups (98.1%, p = 1.00). Periprocedural major adverse cardiac and cerebrovascular events and other major complications were rare in both groups (3.8 vs. 4.7%, p = 0.76). At follow-up, DRT was only detected in the SEC - group (3.8 vs. 0%, p = 1.00). The rates of TEs (SEC - 1.2 vs. SEC + 0%, p = 1.00) after hospital discharge and 1-year mortality (SEC - 12.0 vs. SEC + 11.8%, p = 0.96) were not significantly different between the two groups.
CONCLUSIONS
CONCLUSIONS
Presence of SEC at baseline was not associated with an increased rate of DRT or TEs at 1-year follow-up after LAAO in LAARGE.
Identifiants
pubmed: 37261553
doi: 10.1007/s10840-023-01567-z
pii: 10.1007/s10840-023-01567-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Menke J, Lüthje L, Kastrup A, Larsen J. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010;105(4):502–10. https://doi.org/10.1016/j.amjcard.2009.10.018 .
doi: 10.1016/j.amjcard.2009.10.018
pubmed: 20152245
Pandian JD, Gall SL, Kate MP, Silva GS, Akinyemi RO, Ovbiagele BI, Lavados PM, Gandhi DBC, Thrift AG. Prevention of stroke: a global perspective. Lancet. 2018;392(10154):1269–78. https://doi.org/10.1016/s0140-6736(18)31269-8 .
doi: 10.1016/s0140-6736(18)31269-8
pubmed: 30319114
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498.
doi: 10.1093/eurheartj/ehaa612
pubmed: 32860505
Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767–76. https://doi.org/10.1016/s0140-6736(20)32439-9 .
doi: 10.1016/s0140-6736(20)32439-9
pubmed: 33248499
Skurk C, Landmesser U. Left atrial appendage occlusion for stroke prevention - state of the art as provided in an updated EHRA/EAPCI consensus statement and future perspectives. EuroIntervention. 2020;15(13):1117–9. https://doi.org/10.4244/eijv15i13a207 .
doi: 10.4244/eijv15i13a207
pubmed: 31951209
Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B, ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020;22(2):184. https://doi.org/10.1093/europace/euz258 .
Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin Electrophysiol. 2018;4(12):1629–37. https://doi.org/10.1016/j.jacep.2018.09.007 .
doi: 10.1016/j.jacep.2018.09.007
pubmed: 30573129
Kaneko H, Neuss M, Weissenborn J, Butter C. Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device. Heart Vessels. 2017;32(9):1137–43. https://doi.org/10.1007/s00380-017-0971-x .
doi: 10.1007/s00380-017-0971-x
pubmed: 28477098
Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN, Maini B, Gordon NT, Main ML, Reddy VY. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–85. https://doi.org/10.1161/circulationaha.118.035090 .
doi: 10.1161/circulationaha.118.035090
pubmed: 29752398
Pracon R, Bangalore S, Dzielinska Z, Konka M, Kepka C, Kruk M, Kaczmarska-Dyrda E, Petryka-Mazurkiewicz J, Bujak S, Solecki M, Pskit A, Dabrowska A, Sieradzki B, Plonski A, Ruzyllo W, Witkowski A, Demkow M. Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy. Circ Cardiovasc Interv. 2018;11(3):e005997. https://doi.org/10.1161/circinterventions.117.005997 .
doi: 10.1161/circinterventions.117.005997
pubmed: 29463510
Ito T, Suwa M. Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters. Echo Res Pract. 2019;6(2):R65-r73. https://doi.org/10.1530/erp-18-0083 .
doi: 10.1530/erp-18-0083
pubmed: 30959476
pmcid: 6499934
Backhaus JF, Pflaumbaum A, Krogias C, Kreimer F, Mügge A, Gold R, Gotzmann M. Short- and long-term outcome of patients with spontaneous echo contrast or thrombus in the left atrial appendage in the era of the direct acting anticoagulants. Clin Res Cardiol. 2021;110(11):1811–21. https://doi.org/10.1007/s00392-021-01926-8 .
doi: 10.1007/s00392-021-01926-8
pubmed: 34436659
pmcid: 8563546
Brachmann J, Lewalter T, Akin I, Sievert H, Geist V, Zeymer U, Erkapic D, Mudra H, Pleger S, Hochadel M, Senges J. Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE Registry. J Interv Card Electrophysiol. 2020;58(3):273–80. https://doi.org/10.1007/s10840-019-00635-7 .
doi: 10.1007/s10840-019-00635-7
pubmed: 31707534
Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23(4):961–9. https://doi.org/10.1016/0735-1097(94)90644-0 .
doi: 10.1016/0735-1097(94)90644-0
pubmed: 8106703
Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G, Kefer J, Landmesser U, Nielsen-Kudsk JE, Cruz-Gonzalez I, Sievert H, Tichelbäcker T, Kanagaratnam P, Nietlispach F, Aminian A, Kasch F, Freixa X, Danna P, Rezzaghi M, Vermeersch P, Stock F, Stolcova M, Costa M, Ibrahim R, Schillinger W, Meier B, Park JW. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11(10):1170–9. https://doi.org/10.4244/eijy15m01_06 .
doi: 10.4244/eijy15m01_06
pubmed: 25604089
Landmesser U, Tondo C, Camm J, Diener HC, Paul V, Schmidt B, Settergren M, Teiger E, Nielsen-Kudsk JE, Hildick-Smith D. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590–7. https://doi.org/10.4244/eij-d-18-00344 .
doi: 10.4244/eij-d-18-00344
pubmed: 29806820
Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol. 1985;6(4):744–9. https://doi.org/10.1016/s0735-1097(85)80476-9 .
doi: 10.1016/s0735-1097(85)80476-9
pubmed: 4031288
Seidl K, Rameken M, Drögemüller A, Vater M, Brandt A, Schwacke H, Bergmeier C, Zahn R, Senges J. Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the ludwigshafen observational cardioversion study. J Am Coll Cardiol. 2002;39(9):1436–42. https://doi.org/10.1016/s0735-1097(02)01785-0 .
doi: 10.1016/s0735-1097(02)01785-0
pubmed: 11985904
Yoo J, Song D, Baek JH, Kim YD, Nam HS, Hong GR, Kim J, Lee HS, Heo JH. Poor outcome of stroke patients with atrial fibrillation in the presence of coexisting spontaneous echo contrast. Stroke. 2016;47(7):1920–2. https://doi.org/10.1161/strokeaha.116.013351 .
doi: 10.1161/strokeaha.116.013351
pubmed: 27188406
Bergmann MW, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B, Foley D, Betts TR, Grygier M, Protopopov AV, Stein KM, Boersma LVA. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018;13(17):2003–11. https://doi.org/10.4244/eij-d-17-00672 .
doi: 10.4244/eij-d-17-00672
pubmed: 29313819
Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, Gori T, Meincke F, Protopopov AV, Betts T, Foley D, Sievert H, Mazzone P, De Potter T, Vireca E, Stein K, Bergmann MW. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302–8. https://doi.org/10.1016/j.hrthm.2017.05.038 .
doi: 10.1016/j.hrthm.2017.05.038
pubmed: 28577840
Alkhouli M, Du C, Killu A, Simard T, Noseworthy PA, Friedman PA, Curtis JP, Freeman JV, Holmes DR. Clinical impact of residual leaks following left atrial appendage occlusion: insights from the NCDR LAAO Registry. JACC Clin Electrophysiol. 2022;8(6):766–78. https://doi.org/10.1016/j.jacep.2022.03.001 .
doi: 10.1016/j.jacep.2022.03.001
pubmed: 35387751
pmcid: 9233062
Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37(31):2465–74. https://doi.org/10.1093/eurheartj/ehv730 .
doi: 10.1093/eurheartj/ehv730
pubmed: 26822918
pmcid: 4996118
Messele LF, Khan MZ, Darden D, Agarwal S, Krishan S, Pasupula DK, Asad ZUA, Balla S, Singh GD, Srivatsa UN, Munir MB. Outcomes of percutaneous left atrial appendage occlusion device implantation in atrial fibrillation patients based on underlying stroke risk. Europace. 2023. https://doi.org/10.1093/europace/euad049 .
doi: 10.1093/europace/euad049
pubmed: 36881781
pmcid: 10105852
Freeman JV, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ, Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75(13):1503–18. https://doi.org/10.1016/j.jacc.2019.12.040 .
doi: 10.1016/j.jacc.2019.12.040
pubmed: 32238316
pmcid: 7205034
Sedaghat A, Vij V, Al-Kassou B, Gloekler S, Galea R, Fürholz M, Meier B, Valgimigli M, O’Hara G, Arzamendi D, Agudelo V, Asmarats L, Freixa X, Flores-Umanzor E, De Backer O, Søndergaard L, Nombela-Franco L, McInerney A, Korsholm K, Nielsen-Kudsk JE, Afzal S, Zeus T, Operhalski F, Schmidt B, Montalescot G, Guedeney P, Iriart X, Miton N, Saw J, Gilhofer T, Fauchier L, Veliqi E, Meincke F, Petri N, Nordbeck P, Rycerz S, Ognerubov D, Merkulov E, Cruz-González I, Gonzalez-Ferreiro R, Bhatt DL, Laricchia A, Mangieri A, Omran H, Schrickel JW, Rodes-Cabau J, Nickenig G. Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-registry. Circ Cardiovasc Interv. 2021;14(5):e010195. https://doi.org/10.1161/circinterventions.120.010195 .
doi: 10.1161/circinterventions.120.010195
pubmed: 34003661
Simard T, Jung RG, Lehenbauer K, Piayda K, Pracoń R, Jackson GG, Flores-Umanzor E, Faroux L, Korsholm K, Chun JKR, Chen S, Maarse M, Montrella K, Chaker Z, Spoon JN, Pastormerlo LE, Meincke F, Sawant AC, Moldovan CM, Qintar M, Aktas MK, Branca L, Radinovic A, Ram P, El-Zein RS, Flautt T, Ding WY, Sayegh B, Benito-González T, Lee OH, Badejoko SO, Paitazoglou C, Karim N, Zaghloul AM, Agrawal H, Kaplan RM, Alli O, Ahmed A, Suradi HS, Knight BP, Alla VM, Panaich SS, Wong T, Bergmann MW, Chothia R, Kim JS, Pérez de Prado A, Bazaz R, Gupta D, Valderrabano M, Sanchez CE, El Chami MF, Mazzone P, Adamo M, Ling F, Wang DD, O’Neill W, Wojakowski W, Pershad A, Berti S, Spoon D, Kawsara A, Jabbour G, Boersma LVA, Schmidt B, Nielsen-Kudsk JE, Rodés-Cabau J, Freixa X, Ellis CR, Fauchier L, Demkow M, Sievert H, Main ML, Hibbert B, Holmes DR Jr, Alkhouli M. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol. 2021;78(4):297–313. https://doi.org/10.1016/j.jacc.2021.04.098 .
doi: 10.1016/j.jacc.2021.04.098
pubmed: 34294267
Sedaghat A, Nickenig G, Schrickel JW, Ince H, Schmidt B, Protopopov AV, Betts TR, Gori T, Sievert H, Mazzone P, Grygier M, Wald C, Vireca E, Allocco D, Boersma LVA. Incidence, predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-Insights from the EWOLUTION real world registry. Catheter Cardiovasc Interv. 2021;97(7):E1019-e1024. https://doi.org/10.1002/ccd.29458 .
doi: 10.1002/ccd.29458
pubmed: 33417282
Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42. https://doi.org/10.1016/s0140-6736(09)61343-x .
doi: 10.1016/s0140-6736(09)61343-x
pubmed: 19683639
Ledwoch J, Staubach S, Akin I, Ince H, Zeymer U, Pleger S, Sievert H, Hochadel M, Senges J, Lewalter T, Brachmann J, Mudra H. Anticoagulation versus antiplatelet therapy after percutaneous left atrial appendage closure-subanalysis from the multicenter LAARGE registry. J Interv Card Electrophysiol. 2021. https://doi.org/10.1007/s10840-021-01080-1 .
doi: 10.1007/s10840-021-01080-1
pubmed: 34686928
Ganguli M, Lytle ME, Reynolds MD, Dodge HH. Random versus volunteer selection for a community-based study. J Gerontol A Biol Sci Med Sci. 1998;53(1):M39-46. https://doi.org/10.1093/gerona/53a.1.m39 .
doi: 10.1093/gerona/53a.1.m39
pubmed: 9467432
Vincelj J, Sokol I, Jaksić O. Prevalence and clinical significance of left atrial spontaneous echo contrast detected by transesophageal echocardiography. Echocardiography. 2002;19(4):319–24. https://doi.org/10.1046/j.1540-8175.2002.00319.x .
doi: 10.1046/j.1540-8175.2002.00319.x
pubmed: 12047783